Management of Hyperprolactinemia on Cabergoline

Current Treatment Status Assessment

• The patient's normal testosterone levels indicate restoration of gonadal function, suggesting that prolactin levels are likely controlled, as hyperprolactinemia-induced hypogonadism has resolved, according to the Endocrine Society 2
• Normal laboratory parameters, excluding other endocrine or systemic pathology, are expected in patients responding to cabergoline therapy, as reported by the American Urological Association 2

Monitoring Strategy

• The Endocrine Society recommends checking serum prolactin levels every 3-6 months while on stable cabergoline therapy to confirm sustained normalization 1
• If prolactin has been normalized for at least 2 years, a pituitary MRI should be obtained to assess for residual adenoma, as suggested by the American College of Endocrinology 1

Consideration for Dose Reduction or Discontinuation

• The American College of Endocrinology suggests considering gradual cabergoline dose reduction if prolactin levels have been normalized for at least 2 years, and no visible residual prolactinoma is present on MRI 1
• Tapering the cabergoline dose reduces relapse risk compared to sudden withdrawal, according to the Endocrine Society 1

Important Caveats

• The American Association of Neurological Surgeons recommends monitoring for rhinorrhea, which may indicate CSF leak from tumor shrinkage, particularly if the adenoma invaded the sphenoid bone 3
• The American Psychiatric Association suggests being vigilant for dose-independent psychological effects, including mood changes, depression, aggression, hypersexuality, or impulse control disorders, which are related to dopaminergic activity 1, 3

If Treatment Failure Occurs

• Dopamine agonist resistance is defined as failure to achieve normal prolactin levels and/or less than 50% tumor reduction after 3-6 months of maximally tolerated doses, according to the Endocrine Society 1, 3
• In cases of treatment failure, the American College of Endocrinology recommends offering graduated dose increments up to 3.5 mg/week, or exceptionally up to 7 mg/week, and considering transsphenoidal surgery after multidisciplinary discussion 1, 3